China Inflammatory Bowel Disease Treatment Market Size & Outlook
China inflammatory bowel disease treatment market, 2018-2030 (US$M)
Related Markets
China inflammatory bowel disease treatment market highlights
- The China inflammatory bowel disease treatment market generated a revenue of USD 637.3 million in 2023 and is expected to reach USD 964.9 million by 2030.
- The China market is expected to grow at a CAGR of 6.1% from 2024 to 2030.
- In terms of segment, crohn's disease was the largest revenue generating type in 2023.
- Ulcerative Colitis is the most lucrative type segment registering the fastest growth during the forecast period.
Inflammatory bowel disease treatment market data book summary
| Market revenue in 2023 | USD 637.3 million |
| Market revenue in 2030 | USD 964.9 million |
| Growth rate | 6.1% (CAGR from 2023 to 2030) |
| Largest segment | Crohn's disease |
| Fastest growing segment | Ulcerative Colitis |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Crohn's Disease, Ulcerative Colitis |
| Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
Other key industry trends
- In terms of revenue, China accounted for 3.1% of the global inflammatory bowel disease treatment market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan inflammatory bowel disease treatment market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 468.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inflammatory Bowel Disease Treatment Market Scope
Inflammatory Bowel Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China inflammatory bowel disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 55.64% in 2023. Horizon Databook has segmented the China inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The launch of products is a major strategy used by players in the region. For instance, in July 2021, Tillotts Pharma AG announced the launch of Asacol (800 mg tablets) in China for treatment of moderate to mild ulcerative colitis.
In March 2020, Entyvio by Takeda received approval in China for the treatment of severe to moderate ulcerative colitis patients that are not cured using first-line therapies. The use of biologics is limited in the country, limiting the scope of growth.
Treatment options in the country are antibiotics, immunomodulators, corticosteroids, and aminosalicylates. Increasing involvement of local Chinese players in the development of biosimilars for biological products is expected to drive market growth.
Reasons to subscribe to China inflammatory bowel disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China inflammatory bowel disease treatment market databook
-
Our clientele includes a mix of inflammatory bowel disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into China inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China inflammatory bowel disease treatment market size, by type, 2018-2030 (US$M)
China Inflammatory Bowel Disease Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
